泰莎基因治療公司（納斯達克代碼：TSHA）公佈其季度每股虧損$(0.07)，優於分析師一致預期的$(0.08)，超出預期12.5%。與去年同期每股收益$0.92相比，本次爲107.61%的下降。公司報告季度銷售額爲$202萬，低於分析師預期的$231萬，差距爲12.43%。此外，與去年同期$360萬的銷售額相比，本季度銷售額下降了43.90%。

以上內容來自Benzinga Earnings專欄，原文如下：

Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 107.61 percent decrease over earnings of $0.92 per share from the same period last year. The company reported quarterly sales of $2.02 million which missed the analyst consensus estimate of $2.31 million by 12.43 percent. This is a 43.90 percent decrease over sales of $3.60 million the same period last year.